RAS-mutant leukemia stem cells behave differently from other leukemia stem cells

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Research from the Icahn School of Medicine at Mount Sinai provides new insights into acute myeloid leukemia and its resistance to a common treatment.  The study, published Oct. 30 in Nature, was led by Eirini Papapetrou, professor of oncological sciences at Icahn Mount Sinai. Acute myeloid leukemia is a devastating blood cancer that starts in...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP). 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login